Epoetin alfa is a Recombinant Protein owned by Amgen, and is involved in 68 clinical trials, which were completed.

Epoetin alfa, a glycoprotein containing 165 amino acids is produced by recombinant DNA technology. It contains the identical amino acid sequence of isolated erythropoietin. Erythropoietin which is naturally produced in the body stimulates red blood cell production. Recombinant epoetin has similar biological activity to the endogenous hormone, which induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells, including burst-forming units–erythroid, colony-forming units–erythroid, erythroblasts, and reticulocytes, in bone marrow. It also induces the release of reticulocytes from the bone marrow into the blood stream, where they mature into erythrocytes.

The revenue for Epoetin alfa is expected to reach a total of $4.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Epoetin alfa NPV Report.

Epoetin alfa is currently owned by Amgen. Johnson & Johnson is the other company associated in development or marketing of Epoetin alfa.

Epoetin alfa Overview

Epoetina Alfa (Epogen, Procrit, Espo, Eprex, Prrex, Hemoprex, Erypo) is a erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It is formulated as injection solution for intravenous or subcutaneous route of administration. It is indicated for the treatment of anemia due to chronic kidney disease, zidovudine in HIV-infected patients and chemotherapy in patients with cancer. It is also used in reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery and Eprex (epoetin alfa) is indicated for the treatment of symptomatic anaemia in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin.

Amgen Overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

The company reported revenues of (US Dollars) US$25,979 million for the fiscal year ended December 2021 (FY2021), an increase of 2.2% over FY2020. In FY2021, the company’s operating margin was 29.4%, compared to an operating margin of 35.9% in FY2020. In FY2021, the company recorded a net margin of 22.7%, compared to a net margin of 28.6% in FY2020. The company reported revenues of US$6,652 million for the third quarter ended September 2022, an increase of 0.9% over the previous quarter.

Quick View – Epoetin alfa

Report Segments
  • Innovator (NME)
Drug Name
  • Epoetin alfa
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.